MS and Demyelinating Disorders

Patient data were evaluated over a 3-year period, with analyses from baseline, year 1, and year 2 presented at previous CMSC meetings.

Both diets resulted in patients with MS reporting significant changes on Perceived Deficits Questionnaire scores for fatigue and cognitive dysfunction after 12 weeks of intervention.

An expert discusses real-world data for ofatumumab (Kesimpta; Novartis), the first self-administered anti-CD20 monoclonal antibody, in patients with relapsing multiple sclerosis.

Here's what is coming soon to NeurologyLive.

The NeurologyLive staff compiled highlights from our discussions with experts in one convenient location, following ECTRIMS 2021.

Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]

Jeffrey Bennett, MD, PhD, professor of neurology, University of Colorado, discussed his presentation at ECTRIMS involving the relationship of B-cell depletion and improved outcomes in patients treated with inebilizumab.

Discussing a 6-week, virtual program conducted over Zoom, the founder of First Coast Integrative Medicine, spoke on the use of telehealth and future research efforts for integrative medicine in MS. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

The professor of neurology at the NYU Grossman School of Medicine discussed his findings presented at ECTRIMS 2021, which did not support the hypothesis of a wearing off effect with ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 4 minutes]

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stephen Krieger, MD.

Chaired by Devon Conway, MD, the presentations also feature Cleveland Clinic experts Kedar Mahajan, MD, PhD; Marisa McGinley, DO; and Amy Kunchok, MD. [WATCH TIME: 1 hour, 33 minutes]

Deborah Miller, PhD, commented on strategies to maintain patient-provider communication following the discontinuation of disease-modifying therapies in MS.

The founder of First Coast Integrative Medicine spoke on a 6-week virtual program that introduced IM modalities, including guided journaling, nutrition, and yoga. [WATCH TIME: 3 minutes]

Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.

Ashish Pradhan, MD, the executive director and disease area lead for MS and NMOSD, Genentech, offered insight on a number of presentations at the 2021 ECTRIMS Congress.

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]

The professor of neurology at the NYU Grossman School of Medicine provided context on the preliminary data evaluating antibody response in ocrelizumab-treated patients post-vaccine. [WATCH TIME: 5 mintues]

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the realistic outlook of mesenchymal stem cells and other approaches to progressive MS.

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]

Megan Weigel, DNP, APRN-C, APHN-C, MSCN, discussed findings from a study of integrative medicine via a virtual, 6-week workshop, which produced varied results.

After showing potential remyelination effects, the director of the Multiple Sclerosis Center at Ochsner Health offered her perspective on the latest data for ATA188 in progressive MS. [WATCH TIME: 4 minutes]

The professor of neurology at the NYU Grossman School of Medicine discussed the trial design of VIOLA, a new prospective study evaluating responses to COVID-19 vaccines in patients with MS on ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive.

In the final day’s plenary session at ECTRIMS Congress, Ruth Ann Marrie, MD, PhD, FRCPC, FCAHS, gave a look into some of the notable presentations from the annual meeting.